These

medication records JNK-IN-8 in vitro were reviewed for the dispensing of bisphosphonates, calcium supplements and vitamin D during the follow-up period. After the study period, pharmacists received comparable information on patients who were originally assigned to the control group. This study was not covered by the Medical Research Involving Human Subjects Act (WMO) since the patients were not directly exposed to the intervention, and approval by an ethical committee was not required. Outcome measurements All patients were followed up from baseline until the start of eFT508 concentration osteoporosis prophylaxis or the end of the study period (the date of second data extraction), whichever came first. The primary endpoint was a dispensing of a bisphosphonate. Secondary endpoints were the dispensing of other prophylactic osteoporosis drugs (calcium supplements or vitamin D)

and a dispensing of any prophylactic osteoporosis drug as a composite endpoint (bisphosphonate, calcium supplements or vitamin D, only the first event was counted). Statistical analyses We assumed an event rate of 10 % in the control group over 6 months and an increase to 20 % in the intervention group [18, 21]. With a two-sided alpha of 0.05 and 90 % power, a total sample size of 584 patients was estimated which was increased to 695 patients. Chi-square tests or Fisher’s exact tests were used to determine baseline differences between the comparison groups for categorical variables and independent sample t selleck products tests for continuous variables (p < 0.05). Cox proportional hazard models were used to estimate hazard ratios (HRs) for the start of osteoporosis prophylaxis during the follow-up period by comparing the intervention group to the control group. Hazard ratios were adjusted for covariates that were unevenly distributed between the intervention group and control group (p < 0.05). Cytidine deaminase Patients who did not receive any prescription of glucocorticoids during the follow-up period were

censored at 1 day after baseline. In subgroup analyses, results were stratified by gender, the number of prednisone equivalents (DDDs) received in the 6 months before baseline (67.5–134, 135–270, >270) and age categories (≤70, >70 years) for the primary and composite endpoint. Finally, a Kaplan–Meier plot was used to visualize the time to start of bisphosphonate use after baseline and the proportion of patients being newly treated for GIOP during the study period. This plot was stratified by the randomised intervention. All analyses were performed using SAS, version 9.1. Results During the first data extraction period, 735 patients were selected from the participating pharmacies. Of these patients, 31 (4.2 %) were not eligible for bisphosphonate prophylaxis according to the Dutch guideline.